Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03027934Phase 4Withdrawn

A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response

Role: lead

NCT03551756Unknown

Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease

Role: lead

NCT03746782Completed

Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation

Role: lead

All 3 trials loaded